RxDoctor Payments Data

Todd Waldmann, MD

Urology · Meridian, IDNPI 1104877299

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.4%), food and beverage and education — rather than concentrated in one kind of arrangement. SN Holdings, LLC accounts for 69.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $1,755 and has fallen 87.1% since, to $226 in 2025. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.

$2,686in general payments, 2019–2025

Across 46 payments — averaging $58.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SN Holdings, LLC$2K
  • Bayer$142
  • Johnson & Johnson$112
  • Astellas Pharma US Inc$108
  • Urogpo LLC$98
  • Olympus America Inc.$62
  • plus $303 from 11 others

What the payments were for

  • Travel & lodging$1,35550%
  • Food & beverage$1,21245%
  • Education$1054%
  • Other$151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,686 in reported general payments places this provider in the 40th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$334,178
Medicare patients
697
Services billed
14,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide57$679,259
XtandiEnzalutamide22$267,849
Abiraterone Acetate149$202,461
ErleadaApalutamide11$149,026
MyrbetriqMirabegron63$51,891
OrgovyxRelugolix16$43,335
Trospium Chloride82$6,683
Testosterone38$4,545
Tamsulosin Hcl516$4,524
Potassium Citrate ErPotassium Citrate23$4,400
Silodosin65$3,820
Solifenacin Succinate25$3,342
Finasteride269$2,241
Testosterone Cypionate38$1,680
Alfuzosin Hcl ErAlfuzosin Hcl66$1,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$142$679,25957 claims
Astellas Pharma US IncXtandi, Myrbetriq$108$319,74085 claims
Johnson & JohnsonErleada$112$149,02611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 55 urology providers in Idaho.

Other urology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →